Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma.

Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med. 2001 Aug; 59(2):50-6.

View in: PubMed

© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.